Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells $152,835.44 in Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) CEO Michael Metzger sold 7,412 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $20.62, for a total transaction of $152,835.44. Following the sale, the chief executive officer owned 508,849 shares in the company, valued at approximately $10,492,466.38. The trade was a 1.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Syndax Pharmaceuticals Price Performance

Shares of NASDAQ SNDX opened at $21.01 on Monday. The firm has a market cap of $1.83 billion, a P/E ratio of -5.82 and a beta of 0.46. Syndax Pharmaceuticals, Inc. has a twelve month low of $8.58 and a twelve month high of $22.73. The company has a quick ratio of 4.42, a current ratio of 4.64 and a debt-to-equity ratio of 2.78. The company has a 50 day moving average of $20.67 and a 200 day moving average of $17.07.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SNDX shares. BTIG Research reissued a “buy” rating and issued a $56.00 target price on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price objective on shares of Syndax Pharmaceuticals from $40.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, November 12th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Syndax Pharmaceuticals in a report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. Finally, Wall Street Zen upgraded Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $37.20.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SNDX. Larson Financial Group LLC grew its position in shares of Syndax Pharmaceuticals by 192.2% during the third quarter. Larson Financial Group LLC now owns 2,922 shares of the company’s stock worth $45,000 after purchasing an additional 1,922 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Syndax Pharmaceuticals in the 3rd quarter worth $53,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Syndax Pharmaceuticals by 26.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock worth $89,000 after acquiring an additional 893 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at approximately $66,000. Finally, Tower Research Capital LLC TRC increased its position in Syndax Pharmaceuticals by 103.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after acquiring an additional 4,308 shares during the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.